Your browser doesn't support javascript.
loading
Hepatitis B reactivation risk and physician awareness in rheumatological patients receiving anti-tumor necrosis factor-α treatment
Cure, Osman; Kizilkaya, Bayram; Durak, Serdar; Ilkkilic, Kadir.
Afiliación
  • Cure, Osman; Recep Tayyip Erdogan University. School of Medicine. Department of Rheumatology. Rize. TR
  • Kizilkaya, Bayram; Recep Tayyip Erdogan University Training and Research Hospital. Internal Medicine. Rize. TR
  • Durak, Serdar; Bitlis State Hospital. Department of Gastroenterology. Bitlis. TR
  • Ilkkilic, Kadir; Recep Tayyip Erdogan University. School of Medicine. Department of Hematology. Rize. TR
Rev. Assoc. Med. Bras. (1992, Impr.) ; 70(7): e20240091, 2024. tab
Article en En | LILACS-Express | LILACS | ID: biblio-1565039
Biblioteca responsable: BR1.1
Ubicación: 1806-9282-ramb-70-07-e20240091.xml
ABSTRACT
SUMMARY

OBJECTIVE:

We aimed to evaluate the risk of hepatitis B virus reactivation in rheumatic patients using anti-tumor necrosis factor-alpha drugs and the awareness of physicians about hepatitis B virus reactivation.

METHODS:

Demographic characteristics, pre- and post-treatment hepatitis markers, and laboratory parameters of patients receiving anti-tumor necrosis factor-alpha therapy in our rheumatology clinic were retrospectively examined.

RESULTS:

A total of 448 patients, 240 (53.6%) female and 208 (46.4%) male, were evaluated. Their mean age was 48.02±14.64 years. While HBsAg was examined in 443 (98.9%) patients before treatment, 7 (1.6%) patients were found to be HBsAg positive. While anti-HBc IgG was examined in 405 (90.4%) patients, it was positive in 69 (17%) patients. HBs Ag (total 446-99.6%) test was performed in three patients who were not tested for HBsAg before the treatment, and anti-HBc total (431-96.2% total) test was performed in 26 patients who were not tested for anti-HBc total. All HBsAg positive patients and 17 (24.6%) of those with previous hepatitis B received antiviral treatment. While the median follow-up period of the patients was 24 (6-60) months, no patient developed hepatitis B virus reactivation.

CONCLUSION:

The screening rates and awareness of physicians providing anti-tumor necrosis factor-alpha therapy for hepatitis B virus infection were found to be higher compared to similar studies. Hepatitis B virus reactivation did not develop in any patient. Since the risk of hepatitis B virus reactivation is low, especially in patients with previous hepatitis B, it would be more appropriate to follow up the patients without giving antiviral prophylaxis.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Idioma: En Revista: Rev. Assoc. Med. Bras. (1992, Impr.) Asunto de la revista: Educa‡Æo em Sa£de / GestÆo do Conhecimento para a Pesquisa em Sa£de / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: LILACS Idioma: En Revista: Rev. Assoc. Med. Bras. (1992, Impr.) Asunto de la revista: Educa‡Æo em Sa£de / GestÆo do Conhecimento para a Pesquisa em Sa£de / MEDICINA Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Brasil